BioSpace News Archive

CBSET Inc., a not-for-profit translational research institute, announced that its partner, CILcare, a leading CRO specializing in hearing disorders, has promoted Dr. Wahid Awad to Chief Business Officer ; and, the company further announced that Dr. Awad has been elected to its Board of Directors.

BGI Genomics Co., Ltd. (SZSE:300676), and Saudi Arabia’s National Unified Procurement Company (NUPCO) have signed an agreement to establish Six “Huo-Yan” (“Fire Eye”) laboratories in Saudi Arabia to fight the COVID-19 pandemic. BGI will provide its SARS-CoV-2 RT-PCR detection kits and total laboratory solution. The Huo-Yan l

Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R) as a potential therapy for management of COVID-19 disease.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Prof. Zamir Halpern to its Scientific Board of Advisors.

On March 17, 2020, SignPath Pharma issued a press release stating its intention to pursue a therapeutic treatment for COVID-19 with SignPath’s proprietary patented drug, Lipocurc™. LipoCurc suppresses inflammatory cytokines which can cause cytokine storm. Cytokine storm is believed by many experts to be a significant cause of the lung and organ damage suffered by some COVID-19 patients. SignPath believes that Lipocu

Synaptive Medical, a leader in robotic surgical and imaging technologies, announced today the company has established a partnership with O-Two Medical Technologies, Inc., a world leader in controlled ventilation, for the production of O-Two’s e700 portable transport ventilator for patients impacted worldwide by COVID-19

According to the report, the global angioplasty balloons & stents market was valued at US$ 5.9 Bn in 2018 and is projected to expand at a CAGR of 4.5% from 2019 to 2027

Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees significant growth opportunities in Europe

Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF) (“Predictmedix” or the “Company”) is pleased to announce that it has filed Patent Application Number 63012510 – Artificial Intelligence driven rapid screening system for infectious diseases, such as SARS-CoV-2 virus responsible for COVID-19, with the United States Patent and Trademark Office.

With augmented demand for drugs, incidences are adverse drug reactions are bound to rise, which is likely to pave the way for rapid growth of the global pharmacovigilance market.